STARTUP
PreGenerate GmbH
PreGenerate combines organ on chip know-how, qPCR, and laboratory robotics to realise personalised treatment planning for arthritis patients and their attending orthopaedists. We believe that the key to improving treatment outcomes is focusing on each individual patient. By analysing patient cells on our device with different available treatments, we assess which genes are turned up or down by the specific patient’s cells depending on which treatment is ultimately chosen by the attending surgeon. In future, we will further leverage our data with AI analytics.
PreGenerate's Story
I am a surgeon for horses, the second largest population suffering from arthritis. Our technology was first developed during my time as a senior surgeon and PhD candidate at Vetmeduni Vienna, where I began to see the potential impact of identifying which patients were likely to respond to which arthritis treatment. Then, I tore my meniscus and became the ‘typical’ arthritis patient – under age 60 and female. This is when I learned the fate of human arthritis patients is still unacceptable, not only physically limiting patients but also costing hundreds of billions of dollars every year! Since founding, we’ve carefully selected our time to align with our mission of impacting patients’ lives first and foremost.